

Resource Summary Report

Generated by [dkNET](#) on Aug 3, 2026

B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J

RRID:IMSR_JAX:005236

Type: Organism

Proper Citation

RRID:IMSR_JAX:005236

Organism Information

URL: <https://www.jax.org/strain/005236>

Proper Citation: RRID:IMSR_JAX:005236

Description: Mus musculus with name B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J from IMSR.

Species: Mus musculus

Notes: gene symbol note: T cell receptor beta chain|T cell receptor alpha chain|transgene insertion 416; Satvir S Tevethia; mutant strain|congenic strain: Tcrb|Tcra|Tg(TcraY1;TcrbY1)416Tev

Affected Gene: T cell receptor beta chain|T cell receptor alpha chain|transgene insertion 416; Satvir S Tevethia

Genomic Alteration: transgene insertion 416; Satvir S Tevethia

Catalog Number: JAX:005236

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: embryo

Organism Name: B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J

Record Creation Time: 20250513T053649+0000

Record Last Update: 20260801T050351+0000

Ratings and Alerts

No rating or validation information has been found for B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J.

No alerts have been found for B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. Cell reports, 44(6), 115800.

Kemna J, et al. (2023) IFN γ binding to extracellular matrix prevents fatal systemic toxicity. Nature immunology, 24(3), 414.

Shakiba M, et al. (2022) TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. The Journal of experimental medicine, 219(2).

Li Z, et al. (2019) Mouse CD8+NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells. Cancer immunology, immunotherapy : CII, 68(8), 1303.

Liu D, et al. (2018) Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer. Journal of immunology research and therapy, 3(1), 115.